Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA)
March 11th 2024Experts discuss the Phase 2 D-ALBA trial results examining combination of dasatinib plus blinatumomab as frontline therapy for adults with Philadelphia chromosome-positive B cell acute lymphoblastic leukemia.